Ankylosing Spondylitis Disease Activity Score (ASDAS) by anti-drug

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients, Arthritis Research & Therapy

Algorithm for administration of INX in NOR-DRUM A (visits ≤ week 14)

Worse Scores but Similar Patterns of Disease Activity: Interpreting Outcomes in women with axial spondyloarthropathy - Hospital Professional News

Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C‐reactive protein (ASDAS‐CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore - Kwan

Evaluation of performance of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) in a Brazilian cohort of 1492 patients with spondyloarthritis: data from the Brazilian Registry of Spondyloarthritides (RBE) – topic of research

EULAR Abstract Archive

Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing

Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states

Video Abstract: Simplified Ankylosing Spondylitis Disease Activity Score (SASDAS) Versus ASDAS

SciELO - Brasil - Maintained activity in ankylosing spondylitis patients treated with TNFi and/or NSAID for at least 12 weeks: a cross-sectional study in Brazil Maintained activity in ankylosing spondylitis patients treated

Biosimilar of Remicade Works in Ankylosing Spondylitis

WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents

Validation of the Ankylosing Spondylitis Disease Activity Score with a Quick Quantitative Creactiveprotein Assay (ASDAS-qCRP) in Patients with Axial Spondyloarthritis (axSpA): Aprospective, National, Multicenter Study - ACR Meeting Abstracts

Full article: Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study